With the continuous launch of new varieties of antithrombotic，blood pressure lowering and cholesterol lowering drugs，the situation of clinical medicines has changed. As of the end of 2019，seven large varieties of antithrombotic drugs have successfully passed the consistency evaluation of generic drugs，namely clopidogrel sulfate，ticagrelor，rivaroxaban，apixaban，warfarin，nadroparin calcium injection，and heparin sodium injection. They account for about 18% of the antithrombotic drugs used in hospitals. China is a country with a high incidence of thrombotic diseases. Its biggest feature is that the incidence of stroke is significantly higher than coronary heart disease，which can be called the first killer to endanger health. Driven by rigid demand，the market for antithrombotic drugs has been growing year by year. With the increase in the variety of consistency evaluation and the maturity of the pilot experience in volume-based procurement，the new batch of volume-based procurement will inevitably include more antithrombotic drugs，which will lead to intensified market competition.